Skip to main content
Peter Yi Ch'en on Muck Rack

Peter Yi Ch'en

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter Yi

Contact Peter Yi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Minimal Efficacy of Single-Agent Anti-PD(L)1 Rechallenge in Immunotherapy-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients

|
By Yuzheng Zhang, Daniel Hippe, Peter Yi Ch'en
| preprints.org
You are already at the latest version Background/Objectives: Anti-PD(L)1 immune checkpoint inhibitors (ICI) provide durable responses in nearly 50% of patients with advanced Merkel cell carcinoma (MCC). However, for those progressing on first-line ICI, optimal subsequent therapy remains unclear. Although presumed to have limited benefit, the efficacy of rechallenge with anti-PD(L)1 alone has not been formally reported.
Open in Who Shared Issue with article?
See all 1 articles